Ultra Nasdaq Biotechnology Proshares (BIB) 158.42 $BIB
Biotechs selling off on increased volume
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:13AM CDT
BIS: 34.50 (+1.51), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
SmarTrend Watching for Potential Rebound in Shares of ProShares Ultra Nasdaq Biotechnology ETF After 1.50% Loss
Comtex SmarTrend(R) - Tue Mar 24, 5:12PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $170.41 to a high of $177.33. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $171.00 on volume of 444,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIB: 158.42 (-7.34)
FDA to assess homeopathy business
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:42PM CDT
BIS: 34.50 (+1.51), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89), DRGS: 59.59 (+0.51), IXJ: 107.81 (-1.69), IRY: 51.69 (-0.84)
Shares of BIB Up 22.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 23, 9:24AM CDT
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on February 17th, 2015 at $142.82. In approximately 1 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 22.08% as of today's recent price of $174.35.
BIB: 158.42 (-7.34)
Direxion Plans Two Triple-Leveraged Biotech ETFs - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Fri Mar 20, 9:30AM CDT
Given the high level of volatility and the prospect of big moves in the biotech sector, Direxion plans to launch a pair of ETFs employing triple leverage.
BIB: 158.42 (-7.34), FBT: 118.23 (-2.67), XBI: 225.50 (+1.13)
Pharma and Biotech M&A deals reached $212B last year
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 10:45AM CDT
BIS: 34.50 (+1.51), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89), DRGS: 59.59 (+0.51), IXJ: 107.81 (-1.69), IRY: 51.69 (-0.84)
ProShares Ultra Nasdaq Biotechnology ETF Set to Possibly Pullback After Yesterday's Rally of 1.35%
Comtex SmarTrend(R) - Tue Mar 17, 4:57PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $166.63 to a high of $171.29. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $168.85 on volume of 342,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 158.42 (-7.34)
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 422.24 (-9.38), BBC: 32.83 (-0.63), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13), AMGN: 159.85 (-4.45)
12.6% Return Seen to Date on SmarTrend ProShares Ultra Nasdaq Biotechnology ETF Call (BIB)
Comtex SmarTrend(R) - Fri Mar 13, 5:13PM CDT
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on February 17th, 2015 at $142.82. In approximately 3 weeks, ProShares Ultra Nasdaq Biotechnology ETF has returned 12.64% as of today's recent price of $160.87.
BIB: 158.42 (-7.34)
3 Biotech ETFs Crushing The Market In 2015
Zacks Funds - Seeking Alpha - Fri Mar 13, 3:16PM CDT
As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a number of companies in this sector lately, turning...
BBC: 32.83 (-0.63), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13)
3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 422.24 (-9.38), BBC: 32.83 (-0.63), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), AMGN: 159.85 (-4.45)
Biotech selling off early
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST
BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
Ugly day for biotech
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 1:03PM CST
BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
Biotech off to a good start on first trading day of 2015
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:57AM CST
BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 86.77 (+1.37), GILD: 98.13 (-2.56), FBT: 118.23 (-2.67), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), BBH: 129.58 (-3.38), ABBV: 58.54 (+0.30)
Look for Shares of ProShares Ultra Nasdaq Biotechnology ETF to Potentially Rebound after Yesterday's 9.20% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 5:13PM CST
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $116.34 to a high of $131.99. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $128.10 on volume of 948,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIB: 158.42 (-7.34)
Money flowing out of biotech today
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:40AM CST
BIS: 34.50 (+1.51), ESRX: 86.77 (+1.37), GILD: 98.13 (-2.56), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89), ABBV: 58.54 (+0.30)
ProShares Ultra Nasdaq Biotechnology ETF Has Returned 22.8% Since SmarTrend Recommendation (BIB)
Comtex SmarTrend(R) - Mon Dec 15, 9:19AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 months, ProShares Ultra Nasdaq Biotechnology ETF has returned 22.84% as of today's recent price of $128.68.
BIB: 158.42 (-7.34)
Biotechs selling off on increased volume
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:13AM CDT
BIS: 34.50 (+1.51), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
SmarTrend Watching for Potential Rebound in Shares of ProShares Ultra Nasdaq Biotechnology ETF After 1.50% Loss
Comtex SmarTrend(R) - Tue Mar 24, 5:12PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $170.41 to a high of $177.33. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $171.00 on volume of 444,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIB: 158.42 (-7.34)
FDA to assess homeopathy business
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:42PM CDT
BIS: 34.50 (+1.51), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89), DRGS: 59.59 (+0.51), IXJ: 107.81 (-1.69), IRY: 51.69 (-0.84)
Shares of BIB Up 22.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 23, 9:24AM CDT
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on February 17th, 2015 at $142.82. In approximately 1 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 22.08% as of today's recent price of $174.35.
BIB: 158.42 (-7.34)
Direxion Plans Two Triple-Leveraged Biotech ETFs - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Fri Mar 20, 9:30AM CDT
Given the high level of volatility and the prospect of big moves in the biotech sector, Direxion plans to launch a pair of ETFs employing triple leverage.
BIB: 158.42 (-7.34), FBT: 118.23 (-2.67), XBI: 225.50 (+1.13)
Pharma and Biotech M&A deals reached $212B last year
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 10:45AM CDT
BIS: 34.50 (+1.51), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89), DRGS: 59.59 (+0.51), IXJ: 107.81 (-1.69), IRY: 51.69 (-0.84)
ProShares Ultra Nasdaq Biotechnology ETF Set to Possibly Pullback After Yesterday's Rally of 1.35%
Comtex SmarTrend(R) - Tue Mar 17, 4:57PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $166.63 to a high of $171.29. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $168.85 on volume of 342,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 158.42 (-7.34)
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 422.24 (-9.38), BBC: 32.83 (-0.63), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13), AMGN: 159.85 (-4.45)
12.6% Return Seen to Date on SmarTrend ProShares Ultra Nasdaq Biotechnology ETF Call (BIB)
Comtex SmarTrend(R) - Fri Mar 13, 5:13PM CDT
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on February 17th, 2015 at $142.82. In approximately 3 weeks, ProShares Ultra Nasdaq Biotechnology ETF has returned 12.64% as of today's recent price of $160.87.
BIB: 158.42 (-7.34)
3 Biotech ETFs Crushing The Market In 2015
Zacks Funds - Seeking Alpha - Fri Mar 13, 3:16PM CDT
As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a number of companies in this sector lately, turning...
BBC: 32.83 (-0.63), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13)
3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 422.24 (-9.38), BBC: 32.83 (-0.63), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), AMGN: 159.85 (-4.45)
Biotech selling off early
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST
BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
Ugly day for biotech
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 1:03PM CST
BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
Biotech off to a good start on first trading day of 2015
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:57AM CST
BIB: 158.42 (-7.34), IBB: 343.43 (-7.89)
Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 86.77 (+1.37), GILD: 98.13 (-2.56), FBT: 118.23 (-2.67), BIB: 158.42 (-7.34), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), BBH: 129.58 (-3.38), ABBV: 58.54 (+0.30)
Look for Shares of ProShares Ultra Nasdaq Biotechnology ETF to Potentially Rebound after Yesterday's 9.20% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 5:13PM CST
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $116.34 to a high of $131.99. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $128.10 on volume of 948,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIB: 158.42 (-7.34)
Money flowing out of biotech today
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:40AM CST
BIS: 34.50 (+1.51), ESRX: 86.77 (+1.37), GILD: 98.13 (-2.56), BIB: 158.42 (-7.34), IBB: 343.43 (-7.89), ABBV: 58.54 (+0.30)
ProShares Ultra Nasdaq Biotechnology ETF Has Returned 22.8% Since SmarTrend Recommendation (BIB)
Comtex SmarTrend(R) - Mon Dec 15, 9:19AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 months, ProShares Ultra Nasdaq Biotechnology ETF has returned 22.84% as of today's recent price of $128.68.
BIB: 158.42 (-7.34)
